Our Leadership

A Team of Passionate Leaders

Kymera is led by a seasoned team of established biopharmaceutical leaders with the insights and experience to accelerate our progress and change patient lives.

Join Our Exceptional Team
We welcome like-minded pioneers to join us on our extraordinary journey as we create a culture where diverse perspectives are invited and collaboration is celebrated—all in service of our goal to revolutionize medicine and change patients’ lives.

Management Team

Kymera’s leadership are all dedicated innovators, each with decades of experience in drug discovery, development, and growing companies.
Nello Mainolfi, Ph.D.
Founder, President & CEO
Jeremy Chadwick, Ph.D.
Chief Operating Officer
Ellen Chiniara, JD
Chief Legal Officer and Corporate Secretary
Jared Gollob, MD
Chief Medical Officer
Bruce Jacobs, CFA, MBA
Chief Financial Officer
Karen Weisbach
Head of People and Culture
Juliet Williams, Ph.D.
Head of Research

Board of Directors

Our board is composed of leaders with the experience and perspective to support Kymera’s evolution as we work to improve patients’ lives.
Nello Mainolfi, Ph.D.
Founder, President & CEO
Bruce Booth, DPhil
Chairman and Co-Founder
Felix J. Baker, PhD
Lead Independent Director
Jeff Albers, JD, MBA
Pamela Esposito, PhD
Gorjan Hrustanovic, PhD
John Maraganore, PhD
Leigh Morgan
Victor Sandor, MDCM
Elena Ridloff, CFA


Join Us on Our Mission

We are a team of pioneers dedicated to reinventing the treatment of human disease and reshaping the landscape of healthcare.

Learn More About Our Approach

Company Stats

Kymera is building a fully integrated medicines company to redefine disease treatment.

of employees take pride in working at Kymera
issued or pending patents 
capital raised to advance our pipeline
degrader targeting immunological diseases in clinical studies
Our Leadership is Driving the Field Forward

Kymera’s team is catalyzing progress in the science of TPD with key publications and presentations that unlock insights and showcase our findings.

December 10, 2023
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Hematology (ASH) Annual Meeting and Exposition 2024
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.